2019-06 TRISCEND Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

May 6, 2020

Primary Completion Date

January 5, 2024

Study Completion Date

January 31, 2029

Conditions
Tricuspid Valve RegurgitationHeart Valve DiseasesCardiovascular Diseases
Interventions
DEVICE

Transcatheter Tricuspid Valve Replacement

Replacement of the tricuspid valve through a transcatheter approach

Trial Locations (20)

3010

InselSpital University Hospital Bern, Bern

10032

Columbia University Irving Medical Center / NYPH, New York

10467

Montefiore Medical Center, The Bronx

19104

Hospital of the University of Pennsylvania, Philadelphia

22908

University of Virginia Health System, Charlottesville

30308

Emory University, Atlanta

30309

Piedmont Heart Institute, Atlanta

31076

Clinique Pasteur, Toulouse

33600

CHU Bordeaux, Hôpital Cardiologique Haut Lévêque, Pessac

48202

Henry Ford Hospital, Detroit

60208

Northwestern University, Evanston

75093

Baylor Heart Hopsital Plano, Plano

90048

Cedars-Sinai Medical Center, Los Angeles

94305

Stanford University, Stanford

97239

Oregon Health & Science University, Portland

02114

Massachusetts General Hospital Boston, Boston

02115

Brigham and Women's Hospital, Boston

V6Z1Y6

St. Paul's Hospital Vancouver, Vancouver

M5B 1W8

St. Michael's Hospital, Toronto

G1V 4G5

Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval (IUCPQ-ULaval), Québec

Sponsors
All Listed Sponsors
lead

Edwards Lifesciences

INDUSTRY